Value attributes of advanced therapy medicinal products: a documentary analysis of comments received from stakeholders during reimbursement decisions to England’s National Institute of Health and Care Excellence
Expert Review of Pharmacoeconomics & Outcomes Research · 2025
DOI: 10.1080/14737167.2025.2455405 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Nermina Ferizovic und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Department of Primary Care and Population Health, University College London, London, UK. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Reimbursement Mechanisms, Delivery of Health Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVES: Advanced therapy medicinal products (ATMPs) are transformative healthcare interventions, however, there has been limited research exploring their value. The objective of this study was to conduct a thematic analysis as part of a documentary analysis to identify value attributes of ATMPs. METHODS: As part of the NICE assessment processes in England, stakeholders are invited to provide comments on the technology. Nineteen NICE technology assessments (TAs) related to ATMPs were identified and subsequently included in a thematic analysis. All codes (and themes) were generated inductively from the text to reduce bias. RESULTS: This study found that the attributes of value of ATMPs can be categorized into three themes: treatment factors, innovation factors, and wider factors. That is, attributes of value of these interventions include not only direct treatment factors, although this was the largest category, but also additional factors such as those related to innovation and wider impacts the intervention may have, beyond the patient receiving therapy. CONCLUSIONS: This thematic analysis of stakeholder comments submitted to NICE as part of TAs for ATMPs enhances the understanding of attributes of value of ATMPs. The findings are applicable to a wider geography.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Department of Primary Care and Population Health, University College London, London, UK.
- Comprehensive Clinical Trials Unit, University College London, London, UK.
ORCID-Profile: Nermina Ferizovic
Zitieren
APA
Ferizovic, N., Plackett, R., Clarke, C. S., Hunter, R., & Freemantle, N. (2025). Value attributes of advanced therapy medicinal products: a documentary analysis of comments received from stakeholders during reimbursement decisions to England’s National Institute of Health and Care Excellence. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2455405
Vancouver
Ferizovic N, Plackett R, Clarke CS, Hunter R, Freemantle N. Value attributes of advanced therapy medicinal products: a documentary analysis of comments received from stakeholders during reimbursement decisions to England’s National Institute of Health and Care Excellence. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2455405
BibTeX
@article{Ferizovic2025,
author = {Ferizovic, Nermina and Plackett, Ruth and Clarke, Caroline S and Hunter, Rachael and Freemantle, Nick},
title = {Value attributes of advanced therapy medicinal products: a documentary analysis of comments received from stakeholders during reimbursement decisions to England’s National Institute of Health and Care Excellence},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2025},
doi = {10.1080/14737167.2025.2455405}
}
EUVIMED